logo
Share SHARE
FONT-SIZE Plus   Neg

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A federal government agency has outlined proposals to regulate payday loans as part of efforts to curb debt traps and provide reprieve to cash-strapped borrowers, while ensuring credit supply is not hampered. Toyota, world's best-selling car maker, is set to launch a revamped manufacturing system for more efficiency and a sustainable growth. The first medium sized cars from the new Toyota New Global Architecture will be rolled out this year itself and the system will be fully functional by 2020. The co-pilot of the crashed Germanwings plane appears to have intentionally forced the Duesseldorf-bound Airbus into a rapid descent, which eventually led to a crash in the French Alps, French prosecutors said Thursday. At what correspondents described as a "chilling" news conference, Marseille Prosecutor Brice Robin said audio retrieved from Germanwings black box showed that the co-pilot was in
comments powered by Disqus
Follow RTT